Abstract:Background Phosphoinositide-3-kinase Delta (PI3K delta) plays a key role in B-cell signal transduction and inhibition of PI3K delta is confirmed to have clinical benefit in certain types of activation of B-cell malignancies. Virtual screening techniques have been used to discover new molecules for developing novel PI3K delta inhibitors with little side effects. Method: Computer aided drug design method were used to rapidly screen optimal PI3K delta inhibitors from the Asinex database. Virtual screening based molecular docking was performed to find novel and potential lead compound targeting PI3K delta, at first. Subsequently, drug likeness studies were carried out on the retrieved hits to evaluate and analyze their drug like properties such as absorption, distribution, metabolism, excretion, and toxicity (ADMET) for toxicity prediction. Three least toxic compounds were selected for the molecular dynamics (MD) simulations for 30 ns in order to validate its stability inside the active site of PI3K delta receptor. Results: Based on the present in silico analysis, two molecules have been identified which occupied the same binding pocket confirming the selection of active site. ASN 16296138 (Glide score: - 12.175 kcal/mol, cdocker binding energy: - 42.975 kcal/mol and Delta G(bind) value: - 90.457 kcal/mol) and HAS 00227397 (Glide score: - 10.988 kcal/mol, cdocker binding energy: - 39.3376 kcal/mol and Delta G(bind) value: - 81.953 kcal/mol) showed docking affinities comparatively much stronger than those of already reported known inhibitors against PI3K delta. These two ligand's behaviors also showed consistency during the simulation of protein-ligand complexes for 30000 ps respectively, which is indicative of its stability in the receptor pocket. Conclusion: Compound ASN 16296138 and BAS 00227397 are potential candidates for experimental validation of biological activity against PI3K delta in future drug discovery studies. This study smoothes the path for the development of novel leads with improved binding properties, high drug likeness, and low toxicity to humans for the treatment of cancer.

Bioisosteric Replacements of the Indole Moiety for the Development of a Potent and Selective PI3Kδ Inhibitor: Design, Synthesis and Biological Evaluation

Development of small-molecule inhibitors that target PI3K13

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b] Pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) As a Highly Potent PI3K/mTOR Dual Inhibitor for the Treatment of Acute Myeloid Leukemia

Discovery of (S)-2-amino-n-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) As a Potent and Selective Phosphoinositide 3-Kinase Delta (pi3kδ) Inhibitor.

Design, Synthesis and in Vitro Biological Evaluation of 2-Aminopyridine Derivatives As Novel PI3Kδ Inhibitors for Hematological Cancer.

Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor

Discovery of Novel Quinazoline Derivatives As Potent PI3Kδ Inhibitors with High Selectivity.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Design, Synthesis, and Biological Evaluation of Novel 3-Substituted Imidazo[1,2-A]pyridine and Quinazolin-4(3H)-one Derivatives As PI3Kα Inhibitors.

Discovery and Synthesis of a Novel Series of Potent, Selective Inhibitors of the PI3Kα: 2-Alkyl-chromeno[4,3-c]pyrazol-4(2h)-one Derivatives.

Design, synthesis, and biological evaluation of a series of indolone derivatives as novel FLT3 inhibitors for the treatment of acute myeloid leukemia

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Discovery of Novel Pyrido[3,2-D]pyrimidine Derivatives As Selective and Potent PI3Kδ Inhibitors.

Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments

Identification of Novel PI3Kδ Inhibitors by Docking, ADMET Prediction and Molecular Dynamics Simulations.